MiNK Therapeutics Stock (NASDAQ:INKT)
Previous Close
$0.69
52W Range
$0.57 - $1.90
50D Avg
$0.73
200D Avg
$0.88
Market Cap
$27.87M
Avg Vol (3M)
$36.23K
Beta
0.05
Div Yield
-
INKT Company Profile
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
INKT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| IKNA | Ikena Oncology, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| ADAP | Adaptimmune Therapeutics plc |
| SGMO | Sangamo Therapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| KA | Kineta, Inc. |
| ALVR | AlloVir, Inc. |
| AFMD | Affimed N.V. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| CADL | Candel Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| FBRX | Forte Biosciences, Inc. |